Access Equity Research

News

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Channelchek Investor Community to access equity research, video content, events, and much more. All at no cost. 

Access to Exclusive Content. FREE for Registered Users Only. 

Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.

Welcome to the Channelchek Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Inbox Intel from Channelchek.

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2020/10/govx_logo.png" alt="" class="wp-image-63486" style="width:126px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/govx">Research News and Market Data on GOVX </a>



<a href="https://www.geovax.com/investors/press-releases/geovax-highlights-single-dose-mpox-vaccine-data-at-world-vaccine-congress-2026#"></a>



MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to&nbsp;Two-Dose Regimen



ATLANTA, GA, April 2, 2026&nbsp;- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today highlighted preclinical data presented at the World Vaccine Congress Washington 2026 supporting the potential for a single-dose Modified Vaccinia Ankara (MVA)-based mpox vaccine. The data demonstrate that a novel MVA vaccine construct incorporating an immunomodulatory peptide (“MVA-X”) achieved protective efficacy, comparable to the traditional two-dose MVA regimen, in a murine orthopoxvirus challenge model.



<ul class="wp-block-list">
<li>The presentation, titled “Next-Generation MVA Mpox Vaccines: Harnessing an Immunomodulatory Peptide for Single-Dose Efficacy,” was delivered by Heather Koehler, Ph.D., of Washington State University, during the Immune Profiling track on April 1, 2026.</li>



<li>Single-dose efficacy: the MVA-X vaccine construct achieved complete protection comparable to a two-dose MVA vaccine regimen in a lethal orthopox challenge model, while a single-administration of MVA showed only partial protection.</li>



<li>Durable protection: Protective immunity was maintained through Day 150 post-vaccination, with 100% survival observed in both MVA-X (single-dose) and two-dose MVA groups.</li>



<li>Robust viral control: MVA-X demonstrated significant reduction in lung viral burden, comparable to the two-dose MVA regimen.</li>



<li>Improved clinical outcomes: MVA-X vaccinated animals exhibited minimal weight loss, reduced disease severity, and preserved lung structure.</li>



<li>T cell-driven immunity: Protection in MVA-X vaccinated animals was independent of neutralizing antibodies, supported by enhanced CD4+ and CD8+ T cell responses.</li>
</ul>



Mechanistic Innovation



The MVA-X construct incorporates a peptide designed to transiently modulate the PD-1 immune checkpoint pathway, enhancing T cell activation and durability of immune response during vaccination.



This approach enables:



<ul class="wp-block-list">
<li>Stronger and more sustained T cell responses</li>



<li>Enhanced immune memory</li>



<li>Potential for durable protection with fewer doses</li>
</ul>



This represents a novel application of immune checkpoint modulation within vaccine design.



“These findings provide an important proof-of-concept that the performance of MVA-based vaccines can be enhanced to potentially achieve single-dose protection,” said Mark Newman, Ph.D., Chief Scientific Officer of GeoVax. “The preclinical data demonstrates a clear biological signal that supports continued exploration of immune-enhanced MVA constructs.”



David A. Dodd, Chairman and Chief Executive Officer of GeoVax, added: “As mpox continues to emerge as a recurring global health and biodefense concern, the need for vaccines that are both durable and rapidly deployable has become increasingly clear. An MVA-X vaccine may offer the opportunity to meaningfully improve vaccination coverage, compliance, and outbreak response - particularly in resource-constrained or high-risk environments.”



Dodd further noted: “These results reinforce the strength and flexibility of the MVA platform that underpins our GEO-MVA program. With a defined regulatory pathway in place and preparations underway to initiate a Phase 3 immune bridging study, GeoVax is focused on advancing an MVA vaccine designed to expand global supply, support public health preparedness, and address the limitations of existing options.”



Strategic Context



<ul class="wp-block-list">
<li>Supports Single-Dose Strategy for MVA-based immunization: Potential to simplify vaccination and improve real-world deployment</li>



<li>Aligns with Market Need: Potential to addresses drawbacks of current mpox vaccines, including multi-dose requirements and durability</li>
</ul>



About the Study



The study evaluated MVA-X, an MVA-based vaccine incorporating an immunomodulatory peptide sequence designed to enhance T cell responses. In murine models, animals were challenged with high-dose vaccinia virus at multiple timepoints (Days 55, 90, and 150), with outcomes including survival, viral load, clinical pathology, and immune response.



About GeoVax



GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax’s broader pipeline includes the development of GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit&nbsp;<a href="http://www.geovax.com/">www.geovax.com</a>.



Forward-Looking Statements



This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.



Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Company Contact:



<a href="mailto:info@geovax.com">info@geovax.com</a>



678-384-7220



Media Contact:



Jessica Starman



<a href="mailto:media@geovax.com">media@geovax.com</a>

Research News and Market Data on GOVX 







MVA-X Platform Demonstrates Single-Dose Durable Protection Comparable to&nbsp;Two-Dose Regimen



ATLANTA, GA, April 2, 2026&nbsp;&#8211; GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today highlighted preclinical data presented at the World Vaccine Congress Washington 2026 supporting the potential for a single-dose Modified Vaccinia Ankara (MVA)-based mpox vaccine. The data demonstrate that a novel MVA vaccine construct incorporating an immunomodulatory peptide (“MVA-X”) achieved protective efficacy, comparable to the traditional two-dose MVA regimen, in a murine orthopoxvirus challenge model.




The presentation, titled “Next-Generation MVA Mpox Vaccines: Harnessing an Immunomodulatory Peptide for Single-Dose Efficacy,” was delivered by Heather Koehler, Ph.D., of Washington State University, during the Immune Profiling track on April 1, 2026.



Single-dose efficacy: the MVA-X vaccine construct achieved complete protection comparable to a two-dose MVA vaccine regimen in a lethal orthopox challenge model, while a single-administration of MVA showed only partial protection.



Durable protection: Protective immunity was maintained through Day 150 post-vaccination, with 100% survival observed in both MVA-X (single-dose) and two-dose MVA groups.



Robust viral control: MVA-X demonstrated significant reduction in lung viral burden, comparable to the two-dose MVA regimen.



Improved clinical outcomes: MVA-X vaccinated animals exhibited minimal weight loss, reduced disease severity, and preserved lung structure.



T cell-driven immunity: Protection in MVA-X vaccinated animals was independent of neutralizing antibodies, supported by enhanced CD4+ and CD8+ T cell responses.




Mechanistic Innovation



The MVA-X construct incorporates a peptide designed to transiently modulate the PD-1 immune checkpoint pathway, enhancing T cell activation and durability of immune response during vaccination.



This approach enables:




Stronger and more sustained T cell responses



Enhanced immune memory



Potential for durable protection with fewer doses




This represents a novel application of immune checkpoint modulation within vaccine design.



“These findings provide an important proof-of-concept that the performance of MVA-based vaccines can be enhanced to potentially achieve single-dose protection,” said Mark Newman, Ph.D., Chief Scientific Officer of GeoVax. “The preclinical data demonstrates a clear biological signal that supports continued exploration of immune-enhanced MVA constructs.”



David A. Dodd, Chairman and Chief Executive Officer of GeoVax, added: “As mpox continues to emerge as a recurring global health and biodefense concern, the need for vaccines that are both durable and rapidly deployable has become increasingly clear. An MVA-X vaccine may offer the opportunity to meaningfully improve vaccination coverage, compliance, and outbreak response &#8211; particularly in resource-constrained or high-risk environments.”



Dodd further noted: “These results reinforce the strength and flexibility of the MVA platform that underpins our GEO-MVA program. With a defined regulatory pathway in place and preparations underway to initiate a Phase 3 immune bridging study, GeoVax is focused on advancing an MVA vaccine designed to expand global supply, support public health preparedness, and address the limitations of existing options.”



Strategic Context




Supports Single-Dose Strategy for MVA-based immunization: Potential to simplify vaccination and improve real-world deployment



Aligns with Market Need: Potential to addresses drawbacks of current mpox vaccines, including multi-dose requirements and durability




About the Study



The study evaluated MVA-X, an MVA-based vaccine incorporating an immunomodulatory peptide sequence designed to enhance T cell responses. In murine models, animals were challenged with high-dose vaccinia virus at multiple timepoints (Days 55, 90, and 150), with outcomes including survival, viral load, clinical pathology, and immune response.



About GeoVax



GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax’s broader pipeline includes the development of GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit&nbsp;www.geovax.com.



Forward-Looking Statements



This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.



Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Company Contact:



info@geovax.com



678-384-7220



Media Contact:



Jessica Starman



media@geovax.com

Release - GeoVax Highlights Single-Dose Mpox Vaccine Data at World Vaccine Congress 2026

Biotechnology

GeoVax Labs

GOVX

<figure class="wp-block-image aligncenter"><img src="https://ir.seggmedia.com/sites/g/files/knoqqb102426/themes/site/nir_pid4197/dist/images/logo-whitebg.png" alt=""/></figure>



<a href="http://www.channelchek.com/company/segg">Research News and Market Data on SEG</a>G



April 2, 2026



<a href="https://ir.seggmedia.com/node/11151/pdf" target="_blank" rel="noreferrer noopener">PDF Version</a>



<h3 class="wp-block-heading">Headline Partnership Drives Access to Media, Sponsorship and Investment Opportunities</h3>



FORT WORTH, Texas, April 02, 2026 (GLOBE NEWSWIRE) -- Sports Entertainment Gaming Global Corporation (NASDAQ: SEGG, LTRYW) (the “Company” or “SEGG Media”), the global sports, entertainment, and gaming group, today announced the expansion of its partnership with Soccerex, becoming the official headline sponsor across all global Soccerex events in 2026 and 2027. The partnership spans across Europe, North America, and the Middle East, and will integrate the Sports.com brand into Soccerex’s year-round platform engaging hundreds of industry stakeholders. The timing of this partnership with Soccerex aligns with SEGG Media’s near term objective to complete the acquisition of a European football club.



This partnership provides SEGG Media with direct access to a global pipeline of commercial opportunities across media rights, sponsorship, content distribution, and strategic partnerships. Soccerex events convene decision-makers responsible for billions in annual football-related investment, creating a structured environment to originate proprietary deal flow, evaluate opportunities, and execute revenue-generating transactions aligned with the Company’s growth strategy for the Sports.com brand. The Company expects this partnership to serve as a catalyst for revenue-generating partnerships and strategic transactions across its Sports.com platform.



For nearly 30 years, Soccerex has brought together clubs, leagues, federations, investors, and commercial partners from across the game, creating a trusted meeting point for the conversations, relationships, and opportunities that shape the future of football.



The collaboration will give the Company direct access to senior decision-makers responsible for more than $1 billion in annual football-related commercial spend, while also creating opportunities to contribute to industry dialogue, participate in structured commercial introductions through Soccerex’s Deal Network, and build year-round visibility across Soccerex’s expanding media and digital ecosystem.



Through this partnership, Sports.com will leverage Soccerex’s ecosystem to accelerate:



<ul class="wp-block-list">
<li>Content distribution partnerships;</li>



<li>Sponsorship and brand integration opportunities;</li>



<li>Strategic investments and acquisitions within football; and</li>



<li>Development of Sports.com’s global media and streaming footprint. </li>
</ul>



Garrett Armando Navia, CEO, Soccerex, commented:&nbsp;“Sports.com isn’t just partnering with Soccerex - they’re stepping into the center of the global football ecosystem at a time when the industry is evolving faster than ever.



“For nearly three decades, Soccerex has been the platform where the most important relationships in football are built and where the business of the game moves forward. This partnership brings together two platforms aligned in vision - one focused on being the connective core of the global football economy and the other focused on engagement and innovation.



“Together, we are creating something bigger than events - a year-round system that drives real outcomes, unlocks opportunity, and shapes the next era of the football economy.”



The relationship is structured to generate measurable commercial outcomes by positioning Sports.com within the flow of influence, investment, and innovation across the global football ecosystem. By aligning with Soccerex’s established reach to key industry stakeholders and powerbrokers, the Company will play a central role in creating a more connected, commercially active, and globally relevant football business environment. &nbsp;



Marc Bircham, SEGG Media Chairman added:&nbsp;“For SEGG Media, the timing of this partnership could not be more perfect. As things heat up for the Company in its pursuit of acquiring a European football club, Soccerex is an ideal partner with access to the most trusted and influential stakeholders in the global football business. There is no other platform that convenes this level of decision-making power across the sport.



“We also view this partnership as an execution platform designed to convert access into measurable commercial outcomes and accelerate the monetization of the Sports.com brand.



“This is a partnership built on scale, credibility, and shared ambition - and we are proud to be part of Soccerex’s next chapter as it continues to define the future of football.”



The Company will approach this partnership with a disciplined focus on converting access into measurable outcomes aligned with its broader capital allocation and growth strategy, and expects to provide updates on commercial partnerships, strategic initiatives, and transaction activity arising from this collaboration.



This partnership represents a strategic step in embedding Sports.com within the global football economy and advancing the Company’s broader acquisition-led and revenue-focused growth strategy.



About Soccerex Soccerex is the global football business platform — and for 30 years, the industry’s most trusted meeting place. Operating at the intersection of relationships, capital, deal-making and innovation, Soccerex convenes the most influential stakeholders in football through world-class events, year-round digital engagement, and structured commercial platforms.



About SEGG Media Corporation SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com, TicketStub.com, and Lottery.com. Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.



For additional information, visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=ufbON2cv-UX_gT8MEgyURdlRJUpPCZWwZlg1EYm9jcxC7WZJ5C7eJ1-MGaEjAdY74fp0UThjDr3i0D3dlMDizLg0At0Hd7ccqby61sf3zOg=" rel="noreferrer noopener" target="_blank">www.seggmedia.com</a>&nbsp;or contact media relations&nbsp;<a href="https://www.globenewswire.com/Tracker?data=1yIsfdFckO4LOPWHzp0pMWV3--v0m_pJUaWte_7sYINRi8kjDPXD5EpXKJskTd5aIB3ivHtoCOYiIKNevp6b1gfpNN_Ujhasr_gozV3nZqA=" rel="noreferrer noopener" target="_blank">press@seggmedia.com</a>



Important Notice Regarding Forward-Looking Statements&nbsp;



This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company’s internal accounting controls, additional examination of the preliminary conclusions of such review, the Company’s ability to secure additional capital resources, the Company’s ability to continue as a going concern, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Bid Price Requirement, the Company’s ability to regain compliance with Nasdaq Listing Rules, the Company’s ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.



This press release was published by a CLEAR® Verified individual. <img alt="" src="https://ml.globenewswire.com/media/MzUzNGI0OWItNmIzOC00ZDRiLWI4M2QtZjE2MDllNmQzOGE3LTEyMjExODgtMjAyNi0wNC0wMi1lbg==/tiny/SEGG-Media-Corporation.png">



For additional information, contact media relations at media@seggmediacorp.com.

Research News and Market Data on SEGG



April 2, 2026



PDF Version



Headline Partnership Drives Access to Media, Sponsorship and Investment Opportunities



FORT WORTH, Texas, April 02, 2026 (GLOBE NEWSWIRE) &#8212; Sports Entertainment Gaming Global Corporation (NASDAQ: SEGG, LTRYW) (the “Company” or “SEGG Media”), the global sports, entertainment, and gaming group, today announced the expansion of its partnership with Soccerex, becoming the official headline sponsor across all global Soccerex events in 2026 and 2027. The partnership spans across Europe, North America, and the Middle East, and will integrate the Sports.com brand into Soccerex’s year-round platform engaging hundreds of industry stakeholders. The timing of this partnership with Soccerex aligns with SEGG Media’s near term objective to complete the acquisition of a European football club.



This partnership provides SEGG Media with direct access to a global pipeline of commercial opportunities across media rights, sponsorship, content distribution, and strategic partnerships. Soccerex events convene decision-makers responsible for billions in annual football-related investment, creating a structured environment to originate proprietary deal flow, evaluate opportunities, and execute revenue-generating transactions aligned with the Company’s growth strategy for the Sports.com brand. The Company expects this partnership to serve as a catalyst for revenue-generating partnerships and strategic transactions across its Sports.com platform.



For nearly 30 years, Soccerex has brought together clubs, leagues, federations, investors, and commercial partners from across the game, creating a trusted meeting point for the conversations, relationships, and opportunities that shape the future of football.



The collaboration will give the Company direct access to senior decision-makers responsible for more than $1 billion in annual football-related commercial spend, while also creating opportunities to contribute to industry dialogue, participate in structured commercial introductions through Soccerex’s Deal Network, and build year-round visibility across Soccerex’s expanding media and digital ecosystem.



Through this partnership, Sports.com will leverage Soccerex’s ecosystem to accelerate:




Content distribution partnerships;



Sponsorship and brand integration opportunities;



Strategic investments and acquisitions within football; and



Development of Sports.com’s global media and streaming footprint.




Garrett Armando Navia, CEO, Soccerex, commented:&nbsp;“Sports.com isn’t just partnering with Soccerex &#8211; they’re stepping into the center of the global football ecosystem at a time when the industry is evolving faster than ever.



“For nearly three decades, Soccerex has been the platform where the most important relationships in football are built and where the business of the game moves forward. This partnership brings together two platforms aligned in vision &#8211; one focused on being the connective core of the global football economy and the other focused on engagement and innovation.



“Together, we are creating something bigger than events &#8211; a year-round system that drives real outcomes, unlocks opportunity, and shapes the next era of the football economy.”



The relationship is structured to generate measurable commercial outcomes by positioning Sports.com within the flow of influence, investment, and innovation across the global football ecosystem. By aligning with Soccerex’s established reach to key industry stakeholders and powerbrokers, the Company will play a central role in creating a more connected, commercially active, and globally relevant football business environment. &nbsp;



Marc Bircham, SEGG Media Chairman added:&nbsp;“For SEGG Media, the timing of this partnership could not be more perfect. As things heat up for the Company in its pursuit of acquiring a European football club, Soccerex is an ideal partner with access to the most trusted and influential stakeholders in the global football business. There is no other platform that convenes this level of decision-making power across the sport.



“We also view this partnership as an execution platform designed to convert access into measurable commercial outcomes and accelerate the monetization of the Sports.com brand.



“This is a partnership built on scale, credibility, and shared ambition &#8211; and we are proud to be part of Soccerex’s next chapter as it continues to define the future of football.”



The Company will approach this partnership with a disciplined focus on converting access into measurable outcomes aligned with its broader capital allocation and growth strategy, and expects to provide updates on commercial partnerships, strategic initiatives, and transaction activity arising from this collaboration.



This partnership represents a strategic step in embedding Sports.com within the global football economy and advancing the Company’s broader acquisition-led and revenue-focused growth strategy.



About SoccerexSoccerex is the global football business platform — and for 30 years, the industry’s most trusted meeting place. Operating at the intersection of relationships, capital, deal-making and innovation, Soccerex convenes the most influential stakeholders in football through world-class events, year-round digital engagement, and structured commercial platforms.



About SEGG Media CorporationSEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com, TicketStub.com, and Lottery.com. Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.



For additional information, visit&nbsp;www.seggmedia.com&nbsp;or contact media relations&nbsp;press@seggmedia.com



Important Notice Regarding Forward-Looking Statements&nbsp;



This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company’s internal accounting controls, additional examination of the preliminary conclusions of such review, the Company’s ability to secure additional capital resources, the Company’s ability to continue as a going concern, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Bid Price Requirement, the Company’s ability to regain compliance with Nasdaq Listing Rules, the Company’s ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.



This press release was published by a CLEAR® Verified individual.



For additional information, contact media relations at media@seggmediacorp.com.

Release - SEGG Media Expands Soccerex Partnership, Positioning Sports.com at Center of Global Football Deal Ecosystem

Media &amp; Entertainment

SEGG

SEGG Media Corporation

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2020/10/cvgi_logo.png" alt="" class="wp-image-53353" style="width:152px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/cvgi">Research News and Market Data on CVGI</a>



April 2, 2026



<ul id="_ctrl0_ctl61_divEvergreenNewsAttachments" class="wp-block-list">
<li><a href="https://s204.q4cdn.com/845668686/files/doc_news/CVG-Announces-Sale-Leaseback-Transaction-to-Improve-Balance-Sheet-Strength-2026.pdf" target="_blank" rel="noreferrer noopener">Download(opens in new window)</a></li>
</ul>



NEW ALBANY, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Commercial Vehicle Group (the “Company or “CVG”) (NASDAQ: CVGI), a diversified industrial products and services company, today announced that it has completed a sale-leaseback transaction for its manufacturing facility in Vonore, Tennessee, which generated $16 million in proceeds. The Company used the net proceeds from the transaction to prepay a portion of its existing term loan facility, thereby reducing the Company's leverage profile. Under the terms of the agreement, CVG will lease back the Vonore property for a 20-year term, with an initial annual base rent of approximately $1.4 million for the first year.



“This transaction builds on our recent momentum, providing additional cash flow to deleverage,” said James Ray, President and Chief Executive Officer of CVG. “We continue to deliver on our previously stated objectives, with CVG’s near-term focus being on cash generation and lowering our debt levels. Following this transaction, we believe we are even better positioned to drive future growth and shareholder value at CVG.”



CVG anticipates no disruption to operational activities at the Vonore plant.



In conjunction with this announcement, CVG has reaffirmed its previously issued full-year 2026 outlook provided in its fourth-quarter 2025 earnings materials, released on March 10, 2026.



Company Contact Michelle Hards Vice President, Investor Relations and Corporate Financial Planning and Analysis <a href="mailto:Michelle.Hards@cvgrp.com">Michelle.Hards@cvgrp.com</a>



Investor Relations Contact Ross Collins or Nathan Skown Alpha IR Group <a href="mailto:CVGI@alpha-ir.com">CVGI@alpha-ir.com</a>



About CVG



CVG is a global provider of systems, assemblies and components to the global commercial vehicle market and the electric vehicle market. We deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries and communities we serve. Information about the Company and its products is available on the internet at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=saqyigaf-QV6EgcBR9xadLPhCW0l_k9vr5945LbTdpzuEsxDG1IDbkBJo0OAEazfN25eBplOWT-ny34ezlLcjQ==" rel="noreferrer noopener" target="_blank">www.cvgrp.com</a>.



Forward-Looking Statements



This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. For this purpose, any statements contained herein that are not statements of historical fact, including without limitation, certain statements herein regarding industry outlook, the Company’s expectations for future periods with respect to its plans to improve financial results, the future of the Company’s end markets changes in the Class 8 and Class 5-7 North America truck build rates, performance of the global construction and agricultural equipment business, the Company’s prospects in the wire harness and electric vehicle markets, the Company’s initiatives to address customer needs, organic growth, the Company’s strategic plans and plans to focus on certain segments, competition faced by the Company, volatility in and disruption to the global economic environment, including global supply chain constraints, inflation and labor shortages, tariffs and counter-measures, financial covenant compliance, anticipated effects of acquisitions or divestitures, production of new products, plans for capital expenditures and our results of operations or financial position and liquidity, may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe”, “anticipate”, “plan”, “expect”, “intend”, “will”, “should”, “could”, “would”, “project”, “continue”, “likely”, and similar expressions, as they relate to us, are intended to identify forward-looking statements. The important factors discussed in “Item 1A - Risk Factors” in the Company’s Annual Report on Form 10-K, among others, could cause actual results to differ materially from those indicated by forward-looking statements made herein and presented elsewhere by management from time to time. Such forward-looking statements represent management’s current expectations and are inherently uncertain. Investors are warned that actual results may differ from management’s expectations. Additionally, various economic and competitive factors could cause actual results to differ materially from those discussed in such forward-looking statements, including, but not limited to, factors which are outside our control.



Any forward-looking statement that we make in this press release speaks only as of the date of such statement, and we undertake no obligation to update any forward-looking statement or to publicly announce the results of any revision to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data.<img alt="" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4MzAxMSM3NTE2NDQzIzIwMDc4OTQ="> <img alt="" src="https://ml.globenewswire.com/media/ZTc0ZDRkNDYtYzZiNC00Nzg4LTlmZGEtMGIwNjNhMWFjOGE4LTEwMTk0NjctMjAyNi0wNC0wMi1lbg==/tiny/Commercial-Vehicle-Group-Inc-.png">



<figure class="wp-block-image"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/efae7dce-3084-47ec-b8e7-65c3590f5f9f"><img src="https://ml.globenewswire.com/media/efae7dce-3084-47ec-b8e7-65c3590f5f9f/small/cvg-jpg.jpg" alt="Primary Logo"/></a></figure>



Source: Commercial Vehicle Group, Inc.

Research News and Market Data on CVGI



April 2, 2026




Download(opens in new window)




NEW ALBANY, Ohio, April 02, 2026 (GLOBE NEWSWIRE) &#8212; Commercial Vehicle Group (the “Company or “CVG”) (NASDAQ: CVGI), a diversified industrial products and services company, today announced that it has completed a sale-leaseback transaction for its manufacturing facility in Vonore, Tennessee, which generated $16 million in proceeds. The Company used the net proceeds from the transaction to prepay a portion of its existing term loan facility, thereby reducing the Company&#8217;s leverage profile. Under the terms of the agreement, CVG will lease back the Vonore property for a 20-year term, with an initial annual base rent of approximately $1.4 million for the first year.



“This transaction builds on our recent momentum, providing additional cash flow to deleverage,” said James Ray, President and Chief Executive Officer of CVG. “We continue to deliver on our previously stated objectives, with CVG’s near-term focus being on cash generation and lowering our debt levels. Following this transaction, we believe we are even better positioned to drive future growth and shareholder value at CVG.”



CVG anticipates no disruption to operational activities at the Vonore plant.



In conjunction with this announcement, CVG has reaffirmed its previously issued full-year 2026 outlook provided in its fourth-quarter 2025 earnings materials, released on March 10, 2026.



Company ContactMichelle HardsVice President, Investor Relations and Corporate Financial Planning and AnalysisMichelle.Hards@cvgrp.com



Investor Relations ContactRoss Collins or Nathan SkownAlpha IR GroupCVGI@alpha-ir.com



About CVG



CVG is a global provider of systems, assemblies and components to the global commercial vehicle market and the electric vehicle market. We deliver real solutions to complex design, engineering and manufacturing problems while creating positive change for our customers, industries and communities we serve. Information about the Company and its products is available on the internet at&nbsp;www.cvgrp.com.



Forward-Looking Statements



This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. For this purpose, any statements contained herein that are not statements of historical fact, including without limitation, certain statements herein regarding industry outlook, the Company’s expectations for future periods with respect to its plans to improve financial results, the future of the Company’s end markets changes in the Class 8 and Class 5-7 North America truck build rates, performance of the global construction and agricultural equipment business, the Company’s prospects in the wire harness and electric vehicle markets, the Company’s initiatives to address customer needs, organic growth, the Company’s strategic plans and plans to focus on certain segments, competition faced by the Company, volatility in and disruption to the global economic environment, including global supply chain constraints, inflation and labor shortages, tariffs and counter-measures, financial covenant compliance, anticipated effects of acquisitions or divestitures, production of new products, plans for capital expenditures and our results of operations or financial position and liquidity, may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe”, “anticipate”, “plan”, “expect”, “intend”, “will”, “should”, “could”, “would”, “project”, “continue”, “likely”, and similar expressions, as they relate to us, are intended to identify forward-looking statements. The important factors discussed in “Item 1A &#8211; Risk Factors” in the Company’s Annual Report on Form 10-K, among others, could cause actual results to differ materially from those indicated by forward-looking statements made herein and presented elsewhere by management from time to time. Such forward-looking statements represent management’s current expectations and are inherently uncertain. Investors are warned that actual results may differ from management’s expectations. Additionally, various economic and competitive factors could cause actual results to differ materially from those discussed in such forward-looking statements, including, but not limited to, factors which are outside our control.



Any forward-looking statement that we make in this press release speaks only as of the date of such statement, and we undertake no obligation to update any forward-looking statement or to publicly announce the results of any revision to any of those statements to reflect future events or developments. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data.







Source: Commercial Vehicle Group, Inc.

Release - CVG Announces Sale-Leaseback Transaction to Improve Balance Sheet Strength

Commercial Vehicle Group

CVGI

Industrial

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/cocp-logo-pr-1.png" alt="" class="wp-image-49026" style="width:293px;height:auto"/></figure>



<a href="http://www.channelchek.com/company/cocp">Research News and Market Data on COCP</a>



April 02, 2026



<a href="https://content.equisolve.net/_feaaa695896916cf5c05c8aae190044c/cocrystalpharma/news/2026-04-02_Cocrystal_Pharma_Receives_FDA_Fast_Track_226.pdf" target="_blank" rel="noreferrer noopener">&nbsp;Download as PDF</a>



<ul class="wp-block-list">
<li>FDA Fast Track designation supports accelerated development and expedites regulatory review</li>



<li>Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide economic impact</li>
</ul>



BOTHELL, Wash., April 02, 2026 (GLOBE NEWSWIRE) --&nbsp;<a href="https://www.globenewswire.com/Tracker?data=lI6offAo6dh00Jw02YJO2z8x6NRtzK2V_JMprjUsYFIJOJ6mbily3-9_ZvkzvCiUMZL59_8va7WJdiTkE3QWyHU8WEO03moXVo0HDiorBMw=" rel="noreferrer noopener" target="_blank">Cocrystal Pharma, Inc.</a>&nbsp;(Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection.



FDA Fast Track designation aims to facilitate the development and accelerate the review process for drugs that treat serious conditions and address unmet medical needs. The designation enables early and frequent communication with the FDA throughout the development process, allows for rolling review of a New Drug Application (NDA), and may qualify a product for Priority Review at the time of NDA submission.



CDI-988 was designed and developed as an inhibitor of a highly conserved region of noroviruses, coronaviruses, and other 3CL viral proteases. A Phase 1b norovirus challenge study is underway at Emory University School of Medicine to evaluate CDI-988 to both prevent and treat norovirus infection.



“We are pleased that the FDA has granted Fast Track designation for CDI-988, marking a significant milestone for Cocrystal and a critical step toward helping patients with norovirus,” said Sam Lee, Ph.D., President and co‑CEO of Cocrystal Pharma. “Norovirus infections are highly contagious and can cause acute gastroenteritis, resulting in nausea, vomiting, stomach pain, diarrhea, fatigue, fever and dehydration. While most people recover within a few days, immunocompromised individuals can experience chronic, long-term norovirus infections that can persist for weeks to years. Based on compelling data generated to date, we believe that CDI-988 has the potential to both prevent and treat norovirus infection.



“This designation further validates using our unique structure-based drug discovery technology to design pan-viral antivirals that are effective new treatment options,” added Dr. Lee. “We look forward to more frequent interactions with the FDA with the goal of delivering the first therapeutic and preventive medicine to treat norovirus infections.”



About Norovirus



Norovirus is a leading cause of acute gastroenteritis, responsible for an&nbsp;<a href="https://www.globenewswire.com/Tracker?data=fbsbQuk0sveGdwtYCx5_NpXUvwH-_35eCWNeq9NKlO-xdqWYQph2qeqtOW60NdNgu68DYUwMxsPzqxi0B4dJrqGWNb9BmeaImxZ1mBAZgec_ZENL9nSEoiR8kXEKACsTjobK4OYyIv3C6_VGlVzeH_nuf3qip3Ag0ou-Vl2M2xwCh2mvloizwY942JJGoIEOoj0oo80_oOuugni6xtLKFtubfv_Sj3NVf36vVR5glbEnCF8SxkA6WaN_hNPTy-tsSEz2xVcFtrQR5l4BUaxUfxav9G6zuzLFrJUQcd21XN0=" rel="noreferrer noopener" target="_blank">estimated 685 million global cases each year and approximately $60 billion in worldwide economic impact</a>.&nbsp;<a href="https://www.globenewswire.com/Tracker?data=USij0XNLIBpPMvsXti_cMdoeSLgIdCC5E0dCMx8dz-Zxt1Gl_XxiUlB10eYlvfeGz5uTJToGnIuF9JN0g0vSBPONhHgkilnC1Ou8--9_4i3LtrW6C-4sz5HpGSO6IM8iJeQJorV6HBSB0krqhdLVKQyN34ch4XZ9_t_Um16L3YCdsOS3PS8NZx9qz0UjNaNXt4Obiugjz96ovMsY3iWnB7TVoQrcr5j-J0-ynoWTlvwjeJJwKxX8cx-bhgEPin6dpQDwXwuKzhmo9kZM3w0znkHA9Mc8im289umr5mUw_eTx4tnjflo8V1JhdZXPL6aRYtrVWizqaZnaNHGja_6xRoopM7qx_OV877dh8GmgktI=" rel="noreferrer noopener" target="_blank">In the United States alone, the virus is associated with 21 million infections annually, resulting in around 109,000 hospitalizations, 465,000 emergency department visits, and 900 deaths</a>. The estimated annual economic burden in the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=1MDvr8O4tzWUSzeEfFd_VpTCb71NKvpS6zFWw1g7cPGkfB2wFEbrBPheToEBBfYKKWXTJ04FJJCBcWk8a5NCdXGvZrpMxJk349QAO1-Qu1hpBKGCzXGF2rs97bO9QAvMFoWPiuBlgJWePQONtrD60qPAVyxv94KSX9KZEhm6dTAyW-w_uFhHEninaCpfmvywp-4dYF7_-2dAliEeJivtiMd06c9_pWuyAVg0R7ZcndhVQ7LNZ6-HIZXEAcEdy7PB5lWCfSJEQK4nWMvj5RmB1RNkSs7yFsJ-JUQe3xq2IFyeZnR39Q7y74SAjx4QKfBHF73LWXwxpWTc2duSkrS88oPTfpCWSjPnfLOJK0mADBg=" rel="noreferrer noopener" target="_blank">U.S. exceeds $10.6 billion</a>. In developing nations, norovirus contributes to&nbsp;<a href="https://www.globenewswire.com/Tracker?data=h-U7DT5S4fslv2lUySPShA8IrRyXbiXuyx2XQ6RJ5qW7zeG1Q2_27NVVcsCwCHhoj0HfmCaWPGerfhaJCLHLkGrKRmyyUrvp7GAdlvYiTM21N2whHvrF_FZyok8qgfbxRhXmXPJv2bJgWp_85O5xyyQjArvCP9EiHuVS9nlNKAY6MXt8YIfg9Z-VBe6JwXZZ-ojaUjnaWGLcYNAvwjgilaPF7hxP1rKojNBOKcwio0M4SD8LsLupmhv6FdGW3-55m52czFwSVSttwX77JX9aFkcpm4sAYV8CNCWSZ6Hz8Klna2Xj0Z1bl3En-Dt7d4wSQZ3VpvqnzVeoAcSadmzDQkltm6HtfNHbbfJB1EDpna28aRHpmowXun81fi8HSAE_C-k6dPPOeEhlhasVmh46o5B3043JT3ybstQejUenOfg=" rel="noreferrer noopener" target="_blank">up to 1.1 million hospitalizations and 218,000 pediatric deaths each year</a>.



Cocrystal’s ongoing Phase 1b randomized, double‑blind, placebo‑controlled challenge study (<a href="https://www.globenewswire.com/Tracker?data=KyEl-vjaz98C5onCCSJr5XIujYb7S7XPQCpQVyu_zJzcXgOCZ57jSwvTcIFRG7G64EQQe_oL5KIUWMbdQIgIOtRyaWBQBChu0DcG69kfJO8lKGWqcsmbNtqHl2D3uhOQ" rel="noreferrer noopener" target="_blank">NCT07198139</a>) at Emory University School of Medicine will evaluate CDI‑988 in up to 40 healthy adults. The primary endpoint is a reduction in the incidence of clinical symptoms, with secondary endpoints assessing viral shedding, disease severity, safety, and pharmacokinetics.



About Cocrystal Pharma’s Structure-Based Drug Discovery Platform



Cocrystal is leveraging its structure‑based drug discovery platform technology to design next‑generation antiviral candidates that precisely target viral replication mechanisms. By binding to highly conserved regions of viral enzymes, the Company’s compounds aim to maintain potency against mutating strains while minimizing off‑target effects, offering potentially safer, broad‑spectrum antiviral solutions. This approach streamlines candidate identification and optimization, enabling more rapid progression of promising therapies with robust resistance and safety profiles.



About Cocrystal Pharma, Inc.



Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and rhinoviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create viable antiviral drugs. For further information about Cocrystal, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=dyLpw_DvA_pvADYNnypCF22UqYMnGS7wQs8xnR97sfbsq3mV_MKxFhg-1Teo7a_izTH2tY7uvpHA6zYReyX1yMdt72NxIYVs6npomo3X0jaIF4XjdnpkH_rZvFp3Y0pD" rel="noreferrer noopener" target="_blank">www.cocrystalpharma.com</a>.



Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our plans for more frequent interactions with the FDA and our goals with respect to our norovirus product candidate. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials for and otherwise proceed with studies as well as similar problems with our vendors and our current and any future clinical research organization (CROs) and contract manufacturing organizations, the progress and results of the studies including any adverse findings or delays, the ability of us and our CROs to recruit volunteers for, and to otherwise proceed with, clinical studies, our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of any current and future preclinical and clinical studies, general risks arising from clinical studies, receipt of regulatory approvals, regulatory changes and any adverse developments which may arise therefrom, and general economic adverse effects from the ongoing conflict with Iran. Further information on our risk factors is contained in our filings with the SEC, including the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Investor Contact: Alliance Advisors IR Jody Cain 310-691-7100 <a href="https://www.globenewswire.com/Tracker?data=PKPJCRZ3jzt2rGONSp17IF5jzYPTyVPLf8-wD80B5OEg3x9ghB1sQnMVpAQTOm2onueaXcAnqk2PjdOtw2uMVfly9wlzuTECjEzuVocqixpybWssD_Ziqikw1jWrwt2M" rel="noreferrer noopener" target="_blank">jcain@allianceadvisors.com</a>



# # #



<figure class="wp-block-image"><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/a5071a3a-c592-43ba-bfee-77c2867982ba"><img src="https://ml.globenewswire.com/media/a5071a3a-c592-43ba-bfee-77c2867982ba/small/cocrystal-logo-final-highres-792x612-png.png" alt="Primary Logo"/></a></figure>



Source: Cocrystal Pharma, Inc.



Released April 2, 2026

Research News and Market Data on COCP



April 02, 2026



&nbsp;Download as PDF




FDA Fast Track designation supports accelerated development and expedites regulatory review



Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in worldwide economic impact




BOTHELL, Wash., April 02, 2026 (GLOBE NEWSWIRE) &#8212;&nbsp;Cocrystal Pharma, Inc.&nbsp;(Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its oral, direct-acting protease inhibitor, CDI-988, the first oral antiviral candidate being developed for treatment and prophylaxis of norovirus infection.



FDA Fast Track designation aims to facilitate the development and accelerate the review process for drugs that treat serious conditions and address unmet medical needs. The designation enables early and frequent communication with the FDA throughout the development process, allows for rolling review of a New Drug Application (NDA), and may qualify a product for Priority Review at the time of NDA submission.



CDI-988 was designed and developed as an inhibitor of a highly conserved region of noroviruses, coronaviruses, and other 3CL viral proteases. A Phase 1b norovirus challenge study is underway at Emory University School of Medicine to evaluate CDI-988 to both prevent and treat norovirus infection.



“We are pleased that the FDA has granted Fast Track designation for CDI-988, marking a significant milestone for Cocrystal and a critical step toward helping patients with norovirus,” said Sam Lee, Ph.D., President and co‑CEO of Cocrystal Pharma. “Norovirus infections are highly contagious and can cause acute gastroenteritis, resulting in nausea, vomiting, stomach pain, diarrhea, fatigue, fever and dehydration. While most people recover within a few days, immunocompromised individuals can experience chronic, long-term norovirus infections that can persist for weeks to years. Based on compelling data generated to date, we believe that CDI-988 has the potential to both prevent and treat norovirus infection.



“This designation further validates using our unique structure-based drug discovery technology to design pan-viral antivirals that are effective new treatment options,” added Dr. Lee. “We look forward to more frequent interactions with the FDA with the goal of delivering the first therapeutic and preventive medicine to treat norovirus infections.”



About Norovirus



Norovirus is a leading cause of acute gastroenteritis, responsible for an&nbsp;estimated 685 million global cases each year and approximately $60 billion in worldwide economic impact.&nbsp;In the United States alone, the virus is associated with 21 million infections annually, resulting in around 109,000 hospitalizations, 465,000 emergency department visits, and 900 deaths. The estimated annual economic burden in the&nbsp;U.S. exceeds $10.6 billion. In developing nations, norovirus contributes to&nbsp;up to 1.1 million hospitalizations and 218,000 pediatric deaths each year.



Cocrystal’s ongoing Phase 1b randomized, double‑blind, placebo‑controlled challenge study (NCT07198139) at Emory University School of Medicine will evaluate CDI‑988 in up to 40 healthy adults. The primary endpoint is a reduction in the incidence of clinical symptoms, with secondary endpoints assessing viral shedding, disease severity, safety, and pharmacokinetics.



About Cocrystal Pharma’s Structure-Based Drug Discovery Platform



Cocrystal is leveraging its structure‑based drug discovery platform technology to design next‑generation antiviral candidates that precisely target viral replication mechanisms. By binding to highly conserved regions of viral enzymes, the Company’s compounds aim to maintain potency against mutating strains while minimizing off‑target effects, offering potentially safer, broad‑spectrum antiviral solutions. This approach streamlines candidate identification and optimization, enabling more rapid progression of promising therapies with robust resistance and safety profiles.



About Cocrystal Pharma, Inc.



Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and rhinoviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create viable antiviral drugs. For further information about Cocrystal, please visit&nbsp;www.cocrystalpharma.com.



Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our plans for more frequent interactions with the FDA and our goals with respect to our norovirus product candidate. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;is likely,&#8221; &#8220;will,&#8221; &#8220;expect&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials for and otherwise proceed with studies as well as similar problems with our vendors and our current and any future clinical research organization (CROs) and contract manufacturing organizations, the progress and results of the studies including any adverse findings or delays, the ability of us and our CROs to recruit volunteers for, and to otherwise proceed with, clinical studies, our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of any current and future preclinical and clinical studies, general risks arising from clinical studies, receipt of regulatory approvals, regulatory changes and any adverse developments which may arise therefrom, and general economic adverse effects from the ongoing conflict with Iran. Further information on our risk factors is contained in our filings with the SEC, including the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Investor Contact:Alliance Advisors IRJody Cain310-691-7100jcain@allianceadvisors.com



# # #







Source: Cocrystal Pharma, Inc.



Released April 2, 2026

Release - Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

COCP

Cocrystal Pharma

<figure class="wp-block-image aligncenter is-resized"><a href="https://mma.prnewswire.com/media/1852552/V2X_Color_Logo.html" target="_blank" rel="noreferrer noopener"><img src="https://mma.prnewswire.com/media/1852552/V2X_Color_Logo.jpg" alt="V2X (PRNewsfoto/V2X, Inc.)" style="width:204px;height:auto" title="V2X (PRNewsfoto/V2X, Inc.)"/></a></figure>



<a href="http://www.channelchek.com/company/vvx">Research News and Market Data on VVX </a>



April 02, 2026



<ul id="_ctrl0_ctl55_divEvergreenNewsAttachments" class="wp-block-list">
<li><a href="https://s202.q4cdn.com/296309594/files/doc_news/V2X-Names-Mike-Uster-Chief-Information-Officer-to-Advance-Enterprise-Technology-Strategy-2026.pdf" target="_blank" rel="noreferrer noopener">Download(opens in new window)</a></li>
</ul>



RESTON, Va.,&nbsp;April 2, 2026&nbsp;/PRNewswire/ -- V2X, Inc.&nbsp;(NYSE: VVX) today announced the appointment of Mike Uster as Chief Information Officer, effective immediately. In this role, Uster will lead the company's global information technology strategy, enterprise systems, and digital transformation initiatives, with a focus on strengthening cybersecurity, advancing AI-enabled capabilities, and enabling secure, resilient technology platforms that support V2X's mission-critical operations. He will report directly to Jeremy C. Wensinger, President and Chief Executive Officer at V2X.



Uster brings more than 35 years of experience leading enterprise IT, innovation, and mission-critical technology solutions for government and industry. Most recently, he served as Chief Information Officer, Chief Technology Officer, and Senior Vice President at ManTech, where he led enterprise-wide digital transformation initiatives, cybersecurity modernization, and advanced technology adoption across global operations.



"Mike brings an exceptional depth of experience leading enterprise IT transformation and deploying advanced technologies in support of national security missions," said Wensinger. "His leadership in areas such as zero-trust architecture, secure collaboration platforms, and AI-enabled enterprise solutions will help strengthen V2X's technology foundation and enable us to deliver even greater value to our customers and employees."



During his tenure at ManTech, Uster was instrumental in implementing comprehensive zero-trust architecture, driving secure collaboration capabilities, and embedding AI-enabled technologies to enhance productivity and operational excellence across the enterprise.



Earlier in his career, Uster held roles supporting government and national security missions at Northrop Grumman, Lockheed Martin Skunk Works, RAND Corporation, and TRW Inc.. He joined ManTech in 2005 and progressed through leadership roles spanning IT strategy, business systems, and enterprise service delivery.



Uster holds a Bachelor of Arts in Modern European History from Biola University and is recognized for his strategic vision, commitment to innovation, and ability to develop high-performing technology teams.



About V2X V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission's lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today's toughest challenges across all operational domains.



Investor Contact Mike Smith, CFA Vice President, Treasury, Corporate Development and Investor Relations <a href="mailto:IR@goV2X.com" target="_blank" rel="noreferrer noopener">IR@goV2X.com</a> 719-637-5773



Media Contact Angelica Spanos Deoudes Director, Corporate Communications <a href="mailto:Angelica.Deoudes@oV2X.com" target="_blank" rel="noreferrer noopener">Angelica.Deoudes@oV2X.com</a> 571-338-5195



<img width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=LA25049&amp;sd=2026-04-02">&nbsp;View original content to download multimedia:<a rel="noreferrer noopener" href="https://www.prnewswire.com/news-releases/v2x-names-mike-uster-chief-information-officer-to-advance-enterprise-technology-strategy-302732374.html" target="_blank">https://www.prnewswire.com/news-releases/v2x-names-mike-uster-chief-information-officer-to-advance-enterprise-technology-strategy-302732374.html</a>



SOURCE V2X, Inc.

Research News and Market Data on VVX 



April 02, 2026




Download(opens in new window)




RESTON, Va.,&nbsp;April 2, 2026&nbsp;/PRNewswire/ &#8212; V2X, Inc.&nbsp;(NYSE: VVX) today announced the appointment of Mike Uster as Chief Information Officer, effective immediately. In this role, Uster will lead the company&#8217;s global information technology strategy, enterprise systems, and digital transformation initiatives, with a focus on strengthening cybersecurity, advancing AI-enabled capabilities, and enabling secure, resilient technology platforms that support V2X&#8217;s mission-critical operations. He will report directly to Jeremy C. Wensinger, President and Chief Executive Officer at V2X.



Uster brings more than 35 years of experience leading enterprise IT, innovation, and mission-critical technology solutions for government and industry. Most recently, he served as Chief Information Officer, Chief Technology Officer, and Senior Vice President at ManTech, where he led enterprise-wide digital transformation initiatives, cybersecurity modernization, and advanced technology adoption across global operations.



&#8220;Mike brings an exceptional depth of experience leading enterprise IT transformation and deploying advanced technologies in support of national security missions,&#8221; said Wensinger. &#8220;His leadership in areas such as zero-trust architecture, secure collaboration platforms, and AI-enabled enterprise solutions will help strengthen V2X&#8217;s technology foundation and enable us to deliver even greater value to our customers and employees.&#8221;



During his tenure at ManTech, Uster was instrumental in implementing comprehensive zero-trust architecture, driving secure collaboration capabilities, and embedding AI-enabled technologies to enhance productivity and operational excellence across the enterprise.



Earlier in his career, Uster held roles supporting government and national security missions at Northrop Grumman, Lockheed Martin Skunk Works, RAND Corporation, and TRW Inc.. He joined ManTech in 2005 and progressed through leadership roles spanning IT strategy, business systems, and enterprise service delivery.



Uster holds a Bachelor of Arts in Modern European History from Biola University and is recognized for his strategic vision, commitment to innovation, and ability to develop high-performing technology teams.



About V2XV2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission&#8217;s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today&#8217;s toughest challenges across all operational domains.



Investor ContactMike Smith, CFAVice President, Treasury, Corporate Development and Investor RelationsIR@goV2X.com719-637-5773



Media ContactAngelica Spanos DeoudesDirector, Corporate CommunicationsAngelica.Deoudes@oV2X.com571-338-5195



&nbsp;View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-names-mike-uster-chief-information-officer-to-advance-enterprise-technology-strategy-302732374.html



SOURCE V2X, Inc.

Release - V2X Names Mike Uster Chief Information Officer to Advance Enterprise Technology Strategy

Aerospace &amp; Defense

V2X Inc

The macro environment got more complicated overnight. President Trump's prime-time address Wednesday signaling fresh US military strikes on Iran within the next two to three weeks sent oil prices surging past $110 a barrel and triggered a broad selloff in US Treasuries — a combination that has real consequences for the small and microcap companies ChannelChek covers every day.



US two-year yields climbed as much as six basis points to 3.86%, while 10-year yields rose as high as 4.38% before trimming some of the move. The dollar strengthened against all its Group-of-10 peers. Global bond markets followed suit, with Australian and New Zealand 10-year yields rising more than 10 basis points and European traders pricing in three quarter-point ECB rate hikes this year.



The Fed Is Now Boxed In



Before the Iran conflict escalated in late February, markets had priced in more than two Federal Reserve rate cuts in 2026. Those expectations have been completely erased. Overnight index swaps now reflect a Fed that stays on hold for the remainder of the year — a meaningful pivot that ripples directly into how investors value growth-oriented, capital-dependent smaller companies.



The inflation data is not helping. The ISM's gauge of prices paid for manufacturing inputs climbed to 78.3 in March, remaining at its highest level since mid-2022. That number landed just as oil was spiking, reinforcing the concern that energy-driven inflation isn't transitory — it's structural for as long as the Strait of Hormuz remains closed or threatened.



Fed Chair Jerome Powell said earlier this week that longer-term inflation expectations appear to be in check, but acknowledged officials are closely monitoring the situation. The market isn't waiting for clarity. The arm wrestle between inflation fear and growth concern — as Westpac's Martin Whetton put it — is now the defining tension in fixed income, and it's not resolving anytime soon.



Why This Matters for Small and Microcap



Small and microcap companies feel rate environment shifts more acutely than large caps for a straightforward reason: they depend more heavily on external financing. When rate cut expectations evaporate and credit conditions tighten, the cost of capital rises and the timeline for profitability gets scrutinized harder. Biotech companies burning cash toward clinical readouts, small industrials refinancing debt, and emerging growth companies looking to raise equity — all of them operate in a tougher environment when the Fed is frozen and bond yields are climbing.



The growth risk is equally significant. Higher oil prices function as a tax on consumers and businesses alike. Money managers at PIMCO and JPMorgan Asset Management have already signaled they're positioning for an economic slowdown that will eventually drive a bond market rebound — which would suggest yields come back down, but only after a growth scare first. That sequence — inflation now, slowdown later — is historically difficult for smaller companies to navigate.



The Geopolitical Wildcard



What makes this environment particularly hard to trade is the binary nature of the catalyst. A ceasefire announcement could reverse oil prices and Treasury yields in a session. But as M&amp;G Investments' Andrew Chorlton noted, even a ceasefire is likely to be fragile, and markets may be underestimating the inflationary consequences of a conflict that could continue to flare up unpredictably. The risk premium, he argued, should be higher than where markets are currently pricing it.



For investors focused on small and microcap names, the near-term playbook is one of selectivity — companies with strong balance sheets, near-term catalysts, and limited macro exposure are better positioned to weather the volatility than those dependent on a benign rate environment to execute their growth strategy.



The macro has reasserted itself. Navigate accordingly.

The macro environment got more complicated overnight. President Trump&#8217;s prime-time address Wednesday signaling fresh US military strikes on Iran within the next two to three weeks sent oil prices surging past $110 a barrel and triggered a broad selloff in US Treasuries — a combination that has real consequences for the small and microcap companies ChannelChek covers every day.



US two-year yields climbed as much as six basis points to 3.86%, while 10-year yields rose as high as 4.38% before trimming some of the move. The dollar strengthened against all its Group-of-10 peers. Global bond markets followed suit, with Australian and New Zealand 10-year yields rising more than 10 basis points and European traders pricing in three quarter-point ECB rate hikes this year.



The Fed Is Now Boxed In



Before the Iran conflict escalated in late February, markets had priced in more than two Federal Reserve rate cuts in 2026. Those expectations have been completely erased. Overnight index swaps now reflect a Fed that stays on hold for the remainder of the year — a meaningful pivot that ripples directly into how investors value growth-oriented, capital-dependent smaller companies.



The inflation data is not helping. The ISM&#8217;s gauge of prices paid for manufacturing inputs climbed to 78.3 in March, remaining at its highest level since mid-2022. That number landed just as oil was spiking, reinforcing the concern that energy-driven inflation isn&#8217;t transitory — it&#8217;s structural for as long as the Strait of Hormuz remains closed or threatened.



Fed Chair Jerome Powell said earlier this week that longer-term inflation expectations appear to be in check, but acknowledged officials are closely monitoring the situation. The market isn&#8217;t waiting for clarity. The arm wrestle between inflation fear and growth concern — as Westpac&#8217;s Martin Whetton put it — is now the defining tension in fixed income, and it&#8217;s not resolving anytime soon.



Why This Matters for Small and Microcap



Small and microcap companies feel rate environment shifts more acutely than large caps for a straightforward reason: they depend more heavily on external financing. When rate cut expectations evaporate and credit conditions tighten, the cost of capital rises and the timeline for profitability gets scrutinized harder. Biotech companies burning cash toward clinical readouts, small industrials refinancing debt, and emerging growth companies looking to raise equity — all of them operate in a tougher environment when the Fed is frozen and bond yields are climbing.



The growth risk is equally significant. Higher oil prices function as a tax on consumers and businesses alike. Money managers at PIMCO and JPMorgan Asset Management have already signaled they&#8217;re positioning for an economic slowdown that will eventually drive a bond market rebound — which would suggest yields come back down, but only after a growth scare first. That sequence — inflation now, slowdown later — is historically difficult for smaller companies to navigate.



The Geopolitical Wildcard



What makes this environment particularly hard to trade is the binary nature of the catalyst. A ceasefire announcement could reverse oil prices and Treasury yields in a session. But as M&amp;G Investments&#8217; Andrew Chorlton noted, even a ceasefire is likely to be fragile, and markets may be underestimating the inflationary consequences of a conflict that could continue to flare up unpredictably. The risk premium, he argued, should be higher than where markets are currently pricing it.



For investors focused on small and microcap names, the near-term playbook is one of selectivity — companies with strong balance sheets, near-term catalysts, and limited macro exposure are better positioned to weather the volatility than those dependent on a benign rate environment to execute their growth strategy.



The macro has reasserted itself. Navigate accordingly.

No Cuts, No Ceasefire, No Clarity: The Macro Wall Investors Are Staring Down

Bonds

Federal Reserve

Inflation

Iran

Treasury

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, April 02, 2026



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Private placement financing.&nbsp;Summit Midstream announced a private placement of 1,351,351 shares of its common stock with an affiliate of Tailwater Capital LLC at a price of $31.08 per share to raise $42.0 million. Summit intends to use the net proceeds to reduce borrowings under the company’s asset-based lending credit facility and to fund organic growth capital projects. Following the transaction, Tailwater and its affiliated entities are expected to own ~39% of Summit's outstanding equity.



Updating estimates and valuation.&nbsp;Following the financing, Summit will have 13.8 million common shares, along with 6.5 million Class B shares outstanding for a total of 20.3 million shares. We have made no changes to our revenue or EBITDA estimates, although the higher share count has a minor impact on per share estimates and lowers our valuation per share to $46.00 from $48.50.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/28171">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, April 02, 2026



Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Private placement financing.&nbsp;Summit Midstream announced a private placement of 1,351,351 shares of its common stock with an affiliate of Tailwater Capital LLC at a price of $31.08 per share to raise $42.0 million. Summit intends to use the net proceeds to reduce borrowings under the company’s asset-based lending credit facility and to fund organic growth capital projects. Following the transaction, Tailwater and its affiliated entities are expected to own ~39% of Summit&#8217;s outstanding equity.



Updating estimates and valuation.&nbsp;Following the financing, Summit will have 13.8 million common shares, along with 6.5 million Class B shares outstanding for a total of 20.3 million shares. We have made no changes to our revenue or EBITDA estimates, although the higher share count has a minor impact on per share estimates and lowers our valuation per share to $46.00 from $48.50.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Summit Midstream Corp (SMC) - Private Placement Financing Strengthens Balance Sheet and Enhances Financial Flexibility

Summit Midstream Corporation

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, April 02, 2026



Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Acquisition Completed.&nbsp;The acquisition of Great Lakes Dredge &amp; Dock by Saltchuk Resources was completed on April 1st. Announced on February 11th, Saltchuk paid $17/sh for the outstanding GLDD stock, an enterprise value of approximately $1.5 billion.



Tender Offer.&nbsp;As of the expiration of the tender offer, approximately 53,738,558 shares of Great Lakes common stock were validly tendered and not validly withdrawn pursuant to the tender offer, representing approximately 79.88% of the issued and outstanding shares of Great Lakes common stock. As a result of the completion of the transaction, prior to the opening of trading on the NASDAQ on April 1, 2026, all shares of Great Lakes common stock ceased trading, and all shares of Great Lakes common stock will subsequently be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934.



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/28168">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, April 02, 2026



Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Acquisition Completed.&nbsp;The acquisition of Great Lakes Dredge &amp; Dock by Saltchuk Resources was completed on April 1st. Announced on February 11th, Saltchuk paid $17/sh for the outstanding GLDD stock, an enterprise value of approximately $1.5 billion.



Tender Offer.&nbsp;As of the expiration of the tender offer, approximately 53,738,558 shares of Great Lakes common stock were validly tendered and not validly withdrawn pursuant to the tender offer, representing approximately 79.88% of the issued and outstanding shares of Great Lakes common stock. As a result of the completion of the transaction, prior to the opening of trading on the NASDAQ on April 1, 2026, all shares of Great Lakes common stock ceased trading, and all shares of Great Lakes common stock will subsequently be delisted from NASDAQ and deregistered under the Securities Exchange Act of 1934.



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Great Lakes Dredge &amp; Dock (GLDD) - Acquisition by Saltchuk Completed

GLDD

Great Lakes Dredge &amp; Dock

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, April 02, 2026



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Results weaker than expected.&nbsp;Full year 2025 revenue of $361.9 million was well below our $434.2 million estimate. Management emphasized that the Medicare Advantage market remains in a structural reset heading into 2026, with carriers prioritizing retention, member quality, margin integrity, and disciplined unit economics over enrollment growth. Full year 2025 adj. EBITDA loss estimate of $35.1 million was more than our loss estimate of $29.6 million.&nbsp;



Strategic reset.&nbsp;The company has deliberately reduced Medicare Advantage enrollments where first-renewal economics were unattractive, prioritizing long-term profitability and appropriate consumer plan fit. Importantly, the company managed cash flow despite the significant revenue drop, a testament to its structural cost restructuring.&nbsp;



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/28173">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, April 02, 2026



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Results weaker than expected.&nbsp;Full year 2025 revenue of $361.9 million was well below our $434.2 million estimate. Management emphasized that the Medicare Advantage market remains in a structural reset heading into 2026, with carriers prioritizing retention, member quality, margin integrity, and disciplined unit economics over enrollment growth. Full year 2025 adj. EBITDA loss estimate of $35.1 million was more than our loss estimate of $29.6 million.&nbsp;



Strategic reset.&nbsp;The company has deliberately reduced Medicare Advantage enrollments where first-renewal economics were unattractive, prioritizing long-term profitability and appropriate consumer plan fit. Importantly, the company managed cash flow despite the significant revenue drop, a testament to its structural cost restructuring.&nbsp;



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

GoHealth (GOCO) - Reset Deepens, Long-Term Thesis Intact

GOCO

GoHealth

Insurance

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, April 02, 2026



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



An in-line Q4.&nbsp;Direct Digital reported Q4 revenue of $8.4M (down 7% YoY), reflecting a sharp decline in sell-side activity, partially offset by strong buy-side growth (+28% YoY). Total company revenues of $8.4 million were better than our $7.7 million estimate. Q4 adj. EBITDA loss was in line with expectations, at $3.6 million versus $3.4 million.&nbsp;&nbsp;



Buy-side momentum offsetting structural sell-side decline.&nbsp;The primary driver of the quarter was strength in the buy-side segment, supported by improved customer acquisition, higher conversion rates, and increased contribution from returning customers, while the sell-side business experienced significant contraction due to reduced inventory and strategic deprioritization.&nbsp;



<h2 class="wp-block-heading"> <a href="https://www.channelchek.com/research-reports/28172">Get the Full Report</a></h2>



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, April 02, 2026



Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media &amp; Technology , Noble Capital Markets, Inc.



Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



An in-line Q4.&nbsp;Direct Digital reported Q4 revenue of $8.4M (down 7% YoY), reflecting a sharp decline in sell-side activity, partially offset by strong buy-side growth (+28% YoY). Total company revenues of $8.4 million were better than our $7.7 million estimate. Q4 adj. EBITDA loss was in line with expectations, at $3.6 million versus $3.4 million.&nbsp;&nbsp;



Buy-side momentum offsetting structural sell-side decline.&nbsp;The primary driver of the quarter was strength in the buy-side segment, supported by improved customer acquisition, higher conversion rates, and increased contribution from returning customers, while the sell-side business experienced significant contraction due to reduced inventory and strategic deprioritization.&nbsp;



Get the Full Report



Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Direct Digital Holdings (DRCT) - Buy-Side Pivot Gains Traction

Direct Digital Holdings

DRCT

Media

Footer menu

Contact Me

Feedback

Test form

Event Registration

The NobleCon20 VIP Giveaway

Noble Announcement | 2H 2025 Events

Main menu

The NobleCon20 VIP Giveaway – Terms and Conditions
1. Organizer The NobleCon20 VIP Giveaway (“Contest”) is organized by Noble Financial Group and Channelchek (“Organizers”).
2. Eligibility The Contest is open to legal residents of the United States who are 18 years of age or older at the time of entry. Employees of the Organizers, their affiliates, subsidiaries, advertising and promotion agencies, and immediate family members are not eligible to participate.
3. Contest Period The Contest begins on [Start Date] and ends on October 31, 2024, at 11:59 PM ET. Entries submitted after the Contest Period will not be considered.
4. How to Enter To enter the Contest:
<ul>
<li>You must be a registered and verified Channelchek member.</li>
<li>You must complete the Contest entry form available at [Entry Form URL].</li>
</ul>
5. Prize The prize package includes:
<ul>
<li>Round-trip economy airfare for two (2) to South Florida to attend NobleCon20.</li>
<li>Two (2) hotel rooms for the duration of NobleCon20.</li>
<li>Two (2) tickets to NobleCon20, including access to all official NobleCon20 events.</li>
<li>Two (2) VIP meet-and-greet upgrades to the headline event featuring three (3) of the Sharks from ABC’s Shark Tank.</li>
</ul>
There will be one (1) winner chosen. All travel and accommodations are subject to availability and must be arranged through the Organizers. No substitution, transfer, or cash equivalent of prizes is permitted.
6. Winner Selection The winner will be selected on November 1, 2024. The winner will be notified via email using the contact information provided during entry. If the winner does not respond within seven (7) days of the notification, the Organizers reserve the right to select an alternate winner.
7. General Conditions
<ul>
<li>No purchase is necessary to enter or win.</li>
<li>The Contest is void where prohibited by law.</li>
<li>The prize does not include a presentation slot at NobleCon20.</li>
<li>By participating, entrants agree to be bound by these Terms and Conditions and the decisions of the Organizers, which are final and binding in all respects.</li>
<li>The Organizers reserve the right to disqualify any entry that is incomplete, misdirected, or in violation of these Terms and Conditions.</li>
</ul>
8. Privacy By entering the Contest, you agree that your personal information may be used by the Organizers in accordance with their privacy policies.
9. Limitation of Liability The Organizers are not responsible for any incorrect or inaccurate information, technical failures, or unauthorized intervention in the Contest. The Organizers are not liable for any injury or damage to persons or property resulting from participation in the Contest or acceptance or use of any prize.
10. Contact Information For questions or further information about the Contest, please contact the Organizers at contact@channelchek.com.

NobleCon20 VIP Contest Terms

NobleCon20 VIP Giveaway

Show form on click button

<h3 style="text-align: center;">Enjoying Channelchek?</h3>
There&#8217;s more to explore!
<a href="https://www.channelchek.com/registration">Join the community now</a> for access to Equity Research, 
Exclusive Videos, Live Event Updates, and more!
It&#8217;s absolutely free to join.
<a href="https://www.channelchek.com/registration"><img loading="lazy" decoding="async" class=" wp-image-64177 aligncenter" src="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg" alt="" width="351" height="301" /></a>
<script id="xverse-wallet-provider" src="chrome-extension://idnnbdplmphpflfnlkomgpfbpcgelopg/inpage.js"></script>